Loading…
As of 9 Nov 2026: Brawn Biotech ₹21.90 (m-cap ₹6.57 Cr, P/E 6.9) vs ORTIN GLOBAL ₹13.98 (m-cap ₹11.32 Cr). Compare ROE, ROCE, growth, debt, dividends and 1-year returns.
As of · NSE prices; ratios from company filings
| Metric | Brawn Biotech | ORTIN GLOBAL |
|---|---|---|
| Share price | ₹21.90 | ₹13.98 |
| Day change | +4.04% | −0.92% |
| Market cap | ₹6.57 Cr | ₹11.32 Cr |
| P/EPrice ÷ trailing 12-month earnings per share; blank for a loss. | 6.9 | — |
| P/BPrice ÷ book value per share. | 1.5 | 9.1 |
| ROEReturn on equity. | 24.5% | -46.0% |
| ROCEReturn on capital employed. | 0.0% | -32.1% |
| Sales growth (3Y CAGR) | -8.6% | -59.1% |
| Profit growth (3Y CAGR) | 45.4% | — |
| Debt to equity | 0.00 | 0.81 |
| Dividend yield | 0.00% | 0.00% |
| 1-year price return | +8.9% | +18.6% |
| Promoter holding | 53.0% | 1.2% |
| Industry | Pharmaceuticals | Pharmaceuticals |
Open in the compare tool for price charts from one month to five years, scorecards and more companies.
Each line states which company has the higher or lower figure; none of them is a recommendation.
Ortin Global Ltd is larger, with a market cap of ₹11.32 Cr against ₹6.57 Cr for Brawn Biotech Ltd as of 9 Nov 2026 — about 1.7 times the size.
Ortin Global Ltd has no meaningful P/E right now (a loss over the last twelve months, or no reported earnings), so the two cannot be compared on P/E.
Jivani Markets does not give buy, sell or hold recommendations and is not a SEBI-registered investment adviser or research analyst. The table on this page lays out the facts side by side — price, valuation, returns on capital, growth, debt, dividends and promoter holding — so you can weigh them against your own goals, or with a SEBI-registered adviser.
Prices refresh every few minutes during market hours (delayed by up to 15 minutes) and ratios update when the companies report results. Each number is the same one shown on the two stock pages.